Nxera Pharma Co.,Ltd. (4565.T) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 5Aug 10Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

14.7x

EV/EBITDA

64.9x

Market Cap

JPY 106.58B

MomentumView details →

1D Return

+2.61%

YTD Return

+37.85%

RSI (14)

62.6

ValuationView details →

P/E (Fwd)

14.7x

EV/EBITDA

64.9x

Market Cap

JPY 106.58B

RSI (14)

62.6

MomentumView details →

1D Return

+2.61%

YTD Return

+37.85%

ProfitabilityView details →

Gross Margin

62.58%

Net Margin

−29.15%

EBITDA Margin

−11.97%

ROE (TTM)

−15.67%

ROA (TTM)

−7.48%

Asset Turnover

0.26x

GrowthView details →

Revenue YoY

+10.88%

EPS YoY

—

FCF YoY

−1.62%

Revenue CAGR 3Y

+23.90%

EPS CAGR 3Y

—

EBITDA YoY

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.31x

Current Ratio

2.61x

Quick Ratio

1.86x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

34.23B

Net Income (TTM)

−9.98B

Op. CF (TTM)

−4.93B

Next earningsNov 6, 2026 →

Latest newsMore news →

Nexera Pharma announced it will receive a milestone payment of $8.6 million from Centessa Pharmaceuticals, a subsidiary of Eli Lilly, due to progress in late-stage development of an OX2R agonist.2d ago

Neurocrine Biosciences' IND for NBI-1117567 Phase 2 trial in Alzheimer's cognitive impairment was accepted by the US FDA, triggering a $10 million milestone payment to Nexera Pharma.10d ago

Similar companies

Oncolys BioPharma Inc.4588.T Mochida Pharmaceutical Co.,Ltd.4534.T ZERIA PHARMACEUTICAL CO.,LTD.4559.T PeptiDream Inc.4587.T GNI Group Ltd.2160.T EIKEN CHEMICAL CO.,LTD.4549.T Find similar companies →

Latest newsMore news →

Nexera Pharma announced it will receive a milestone payment of $8.6 million from Centessa Pharmaceuticals, a subsidiary of Eli Lilly, due to progress in late-stage development of an OX2R agonist.2d ago Neurocrine Biosciences' IND for NBI-1117567 Phase 2 trial in Alzheimer's cognitive impairment was accepted by the US FDA, triggering a $10 million milestone payment to Nexera Pharma.10d ago